Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04388813 · ClinicalTrials.gov registry record
Predictors of Severe COVID-19 Outcomes
A clinical trial, sponsored by Verily Life Sciences.
- Completed
- Registry status
- 494
- Enrollment target
NCT04388813 is a clinical trial that has completed, run by Verily Life Sciences. The registered enrollment target is 494 participants.
The verdict
NCT04388813 has completed, sponsored by Verily Life Sciences.
- COMPLETED
- Registry status
- 494 participants
- Enrollment target
Study Summary
This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in patients presenting to the hospital with suspicion or diagnosis of COVID-19. We seek to understand whether there are early signatures that predict progression to ARDS, mortality, and/or other comorbid conditions. The duration of the study participation is approximately 3 months.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 494 participants |
| Start Date | 2020-05-28 |
| Est. Completion | 2021-09-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04388813
The ClinicalTrials.gov registry entry for NCT04388813 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verily Life Sciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04388813 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04388813 about?
NCT04388813 is a clinical study titled "Predictors of Severe COVID-19 Outcomes". This is a longitudinal, multi-center, observational study collecting diverse biological measurements and clinical and epidemiological data for the purpose of enabling a greater understanding of the onset of severe outcomes, primarily acute respiratory distress syndrome (ARDS) and/or mortality, in pa...
What is the current status of trial NCT04388813?
This trial is currently completed. The enrollment target is 494 participants. The study started on 2020-05-28. Estimated completion is 2021-09-23.
Who is sponsoring clinical trial NCT04388813?
This trial is sponsored by Verily Life Sciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.